TY - JOUR
T1 - Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE)
T2 - A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
AU - the GOLDMINE consortium
AU - Sharpton, Suzanne
AU - Díaz, Luis Antonio
AU - Pepin, Kay
AU - Amangurbanova, Maral
AU - Madamba, Egbert
AU - Bettencourt, Ricki
AU - Singh, Seema
AU - Valasek, Mark
AU - Dalupang, Mary
AU - Tesfai, Kaleb
AU - Middleton, Michael S.
AU - Behling, Cynthia
AU - Dunn, Winston
AU - Nakajima, Atsushi
AU - Imajo, Kento
AU - Ogawa, Yuji
AU - Caussy, Cyrielle
AU - Halegoua-DeMarzio, Dina
AU - Mohanty, Arpan
AU - Huang, Daniel Q.
AU - Fuchs, Michael
AU - Hameed, Bilal
AU - Stine, Jonathan G.
AU - Balakrishnan, Maya
AU - Gray, Meagan
AU - Rodriguez, Manuel
AU - DeLeon, Andre
AU - Puskoor, Rohit
AU - Vuppalanchi, Raj
AU - Behari, Jaideep
AU - Hansen, Lars
AU - Miller, Cynthia
AU - Medici, Valentina
AU - Sarkar, Souvik
AU - Boursier, Jerome
AU - Tincopa, Monica
AU - Ajmera, Veeral
AU - Richards, Lisa
AU - Sirlin, Claude B.
AU - Ehman, Richard L.
AU - Loomba, Rohit
N1 - Publisher Copyright:
© 2026 John Wiley & Sons Ltd.
PY - 2026/8
Y1 - 2026/8
N2 - Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes. Aims: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasive imaging biomarkers predict MASLD progression and liver-related clinical outcomes. Methods: GOLDMINE is an investigator-initiated, multi-centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy-proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration-controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton-density-fat-fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2-year intervals (years 2 and 4), with annual follow-up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results: The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver-related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, with independent central adjudication of all events. Conclusions: GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI-based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood-based prognostic biomarkers in MASLD.
AB - Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes. Aims: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasive imaging biomarkers predict MASLD progression and liver-related clinical outcomes. Methods: GOLDMINE is an investigator-initiated, multi-centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy-proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration-controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton-density-fat-fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2-year intervals (years 2 and 4), with annual follow-up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results: The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver-related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, with independent central adjudication of all events. Conclusions: GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI-based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood-based prognostic biomarkers in MASLD.
KW - NAFLD
KW - fatty liver
KW - metabolic dysfunction-associated steatotic liver disease
KW - non-alcoholic fatty liver disease
KW - non-alcoholic steatohepatitis
UR - https://www.scopus.com/pages/publications/105036693116
UR - https://www.scopus.com/pages/publications/105036693116#tab=citedBy
U2 - 10.1111/apt.70696
DO - 10.1111/apt.70696
M3 - Article
C2 - 42017265
AN - SCOPUS:105036693116
SN - 0269-2813
VL - 64
SP - 334
EP - 344
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 3
ER -